Therapeutic Nuclear Medicine Market Growth Opportunities: 2034

Therapeutic Nuclear Medicine Market Outlook for 2024 to 2034

The therapeutic nuclear medicine market is foreseen to register a CAGR of 4.10% from 2024 to 2034, with a market valuation of US$ 1.32 billion in 2024. Developing demand is invoked to set a valuation of US$ 1.97 billion in 2034 for the market.

Attributes	Details
Market Value for 2024	US$ 1.32 billion
Market Value for 2034	US$ 1.97 billion
Market Forecast CAGR for 2024 to 2034	4.10%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Consumption Analysis of Therapeutic Nuclear Medicines

Demand for therapeutic nuclear medicine is emerging as the incidence of cancers, bone deformities, and neurological malignancies rises in developing nations.
Development in diagnosis technology encouraging the use of radiopharmaceuticals to diagnose and treat cancerous tumors contributes to the evolution of the market.
Demand for nuclear medicines is experiencing evolution due to a vigorous product pipeline and promising government endeavors to enhance access to nuclear medication.
Awareness and utility of radioisotopes in nuclear medicine therapeutics propose novel prospects for research and development, thereby propelling market growth in the forthcoming decade.
Market value is lowering due to radiation safety concerns, contamination, and the brief half-life of radionuclides.

Historical Performance and Future Growth of the Therapeutic Nuclear Medicine Market

The historical CAGR of 11.70% was recorded for the market and a 4.10% CAGR is calculated through 2034. The market is evolving with the introduction of the product in palliative therapy, taking advantage of the lack of response to different treatments for distressing bone metastasis.

Attributes	Details
Historical CAGR for 2019 to 2023	11.70%

Acute aspects that are anticipated to influence the demand for the product through 2034 include:

Prevalence of cancers, bone deformities, and neurological malignancies develops research opportunities related to nuclear medicine.
Global establishments are anticipated to diminish chronic diseases at their initial stages, thus limiting the need for the treatment in the forthcoming decade.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Key Trends Influencing the Therapeutic Nuclear Medicine Market

Cancer and Cardiovascular Diseases See Stakes Rise in the Demand for the Market

Prevalence of cancers and cardiovascular diseases is primarily propelling the market.
The American Cancer Society reported in 2022, around 268,490 prostate cancer cases and approximately 34,500 deaths, with 6 out of 10 diagnosed being men over 65 and rare in those under 40. Therapeutic nuclear medication is envisioned to significantly contribute to diagnosing and treating cancers and cardiovascular diseases in the forthcoming decade.

The Geriatric Population Demands Innovation in the Industry

Global geriatric population is experiencing a surge in cardiovascular diseases, leading to a significant demand for innovation in nuclear medicines.
Upsurge in cancer patients above 65 necessitates the application of the medicine for detection and treatment, making this vital for geriatric health.
Geriatric patients are anticipated to have low immunity to cardiovascular diseases, leading to an advanced consumer base for therapeutic nuclear medication and treatment.

Establishments Perform Novel Research and Development in Therapeutic Nuclear Medicine

Establishments such as hospitals and research institutes globally focus on developing nuclear medicine therapies due to their superior clinical effects compared to other treatments. For instance, FUJIFILM Toyama Chemical Co., Ltd. launched Lutathera injection in August 2021, a therapeutic medication targeting neuroendocrine tumors.
Novel nuclear medicines have seen greater demand among patients and physicians, enabling pharmaceutical manufacturers to develop more efficient treatments.
Demand for nuclear medicine therapies in countries with high cancer burdens is divined to advance due to improvements in therapeutic applications and outcomes.

Category-wise Insights

The following part offers an in-depth segmental analysis of the therapeutic nuclear medicine market. The demand for Radium-223 is significant, whereas the demand for prostate cancer treatment is anticipated to be augmented in 2024.

Radium-223 Captures Around 77.5% of Market Share

Attributes	Details
Top Radionuclide Type	Radium-223
Market share in 2024	77.50%

The demand for Radium-223 is significant, slotted in to acquire a market share of 77.5% in 2024. The following aspects aid the development of demand for Radium-223:

Researchers are exploring the potential of Radium-223, a small molecule, to treat advanced prostate cancer and induce immune changes earlier in the disease, using radiation to kill cancer cells.
In May 2013, the United States Food and Drug Administration (FDA) approved radium Ra 223 dichloride to treat tumors.
The demand for Radium-223 is significant as it is utilized in cancer therapy through sealed and unsealed sources, to inhibit tumor growth.

Prostate Cancer Accounts for 55.6% of Market Share

Attributes	Details
Top Indication	Prostate Cancer
Market share in 2024	55.60%

Prostate cancer is penned in to acquire a market share by indication of 55.6% in 2024. The following aspects aid the development of the medicines in prostate cancer treatment:

Scientists are studying the treatment for prostate cancer, and so far, they have established several nuclear medicines that are likely to aid in cancer recovery.
In December 2020, the United States Food and Drug Administration approved Gallium 68 PSMA-11, the medicine for PET imaging to diagnose prostate cancer.

Country-wise Insights

According to derived data, the demand from European countries is supposed to augment the sales growth of the medicines in the forthcoming decade. The industry in France and Germany is developing steeply. The therapeutic nuclear medication industry in the United Kingdom is anticipated to register a subordinate CAGR compared to other European nations. The demand for treatment is developing rapidly in Italy and Russia.

Countries	CAGR from 2024 to 2034
Russia	6.4%
Germany	4.4%
Italy	5.4%
United Kingdom	3.5%
France	5.0%

Russian Healthcare Companies Innovate in the Therapeutic Nuclear Medicine Industry

Through 2034, the therapeutic nuclear medicine industry in Russia is anticipated to register a 6.4% CAGR, owing to the development of prominent and emerging pharmaceutical and neurological research organizations.

In Russia, nuclear medicine is used to diagnose and treat various diseases, particularly cardiovascular and neurological conditions, but the key focus has always been placed on oncology.

Chronic Illnesses of German Populace Demands Radiopharmaceutical Therapies

The demand for these medicines is projected to report a CAGR of 4.4% in Germany by 2034 due to the prevalence of chronic diseases such as neuroendocrine tumors, prostate cancer, meningiomas, thyroid cancer, and lymphoma.

As therapeutic nuclear drugs are considered effective drugs for the treatment of cancer in the initial stages, thus German research and development organizations are developing novel radiopharmaceutical therapies.

Although therapeutic nuclear treatments’ future seems promising in the country, the German health regulatory bodies plummet the growth rate of radiopharmaceutical therapies.

Italian Geriatric Population Nurtures the Demand for Therapeutic Nuclear Medicine

The demand for these medicines in Italy is anticipated to showcase a CAGR of 5.4% between 2024 and 2034 as geriatric patients grow nationwide. The Italian medical environment targets the research and development of effective nuclear treatments that can aid in senior health.

French Healthcare Supports the Sales Growth of Therapeutic Nuclear Medicine

The demand for these medicines in France is projected to report a CAGR of 5.0% from 2024 to 2034, as the French field of nuclear medicine and theranostics is developing rapidly. France has over two hundred nuclear medicine departments that use radionuclides for diagnostic or therapeutic objectives in various domains such as oncology, cardiology, neurology, or endocrinology. The medical community is promoting therapeutic nuclear treatment in healthcare environments.

Climate Shift in the United Kingdom Promotes the Sales Growth of Nuclear Medicine Therapeutics

Sales of therapeutic nuclear medicines in the United Kingdom are set to witness a CAGR of 3.5% through 2034. Therapeutic nuclear medicine in the United Kingdom has developed fairly inconsistently over the last half-century.

Nonetheless, the regular climate shifts in the United Kingdom have created a prevalence of cardiovascular illnesses, necessitating the use of therapeutic nuclear medication. The rising geriatric population in the United Kingdom demands innovation in radioisotope therapies aiding in the treatment of prostate cancer.

Market Players Shaping the Outlook of the Therapeutic Nuclear Medicine Market

The therapeutic nuclear medicine industry’s dynamics are changing, and the key market players are vying for the majority stake in the competitive environment. Market players are implementing organic marketing techniques such as mergers and acquisitions, collaborations, and product launches to acquire a competitive advantage.

Top players produce the majority of nuclear medicine treatment products. Industry leaders have built their position in the market by investing more in research and having a better distribution system.

Recent technological developments in nuclear imaging modalities and the introduction of innovative pharmaceuticals into the global market have given the industry a huge boost. Continued and persistent research and development activities that result in betterment in new application areas are pushing market expansion.

Recent Developments in the Therapeutic Nuclear Medicine Market

In February 2024, The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a Mid-Winter Meeting in Orlando, drawing over 700 professionals from various fields to learn from experts and enhance patient care.
In January 2024, The University of Texas MD Anderson Cancer Center partnered with the International Atomic Energy Agency (IAEA) to establish an IAEA Collaborating Centre, directing to improve global radiation oncology, radiation physics, radiology, nuclear medicine, and nutrition, focusing on healthcare.
In January 2024, BARC's Radiation Medicine Research Centre (RMRC) in Kolkata launched advanced Nuclear Medicine services, including FDG PET/CT imaging. The center aspires to provide affordable, advanced diagnostic and therapeutic services in India's Eastern and northeastern states while providing medical and science graduate training and R&D efforts in Nuclear Medicine imaging and radiopharmaceutical development.
In July 2023, The International BRICS Expert Forum on Nuclear Medicine in Moscow attracted over 200 representatives from Russia, Brazil, India, China, and South Africa to discuss progressions in radionuclide diagnostics, disease treatment, and medical device development.

Key Companies in the Therapeutic Nuclear Medicine Market

Bayer AG
GE Healthcare
Novartis AG
Cardinal Health Inc.
Mallinckrodt plc.
Lantheus Medical Imaging Inc.
Bracco Imaging S.p.A
Eckert & Ziegler
Curium Pharma
International Isotopes Idaho, Inc.
Medi-Radiopharma Co., Ltd.

Key Coverage in the Therapeutic Nuclear Medicine Market Report

Growth Analysis of Targeted Radionuclide Therapy in the United States
Growth Analysis of the Radiopharmaceutical Therapy Industry
Assessment of Emerging Trends in Therapeutic Nuclear Medicine
Overview of Therapeutic Nuclear Medicine Industry in the United States
Market Dynamics of Nuclear Medicine Therapeutics

Key Segments

By Treatment Type:

Radium-223
Iodine-131
Leutitium-177
Yttrium-90
Samarium-153
Strontium-89
Rhenium-188+Rhenium-186
Erbium- 169
Phosphorous-32
Others

By Indication:

Prostate Cancer
Painful Bone Metastases
Thyroid Cancer
Neuroblastoma
Synovitis
Non-Hodgkin’s Lymphoma
Hepatic Metastases
Brain Tumour
Others

By Distribution Channel:

Hospitals
Ambulatory Surgical Centers
Cancer Research Institutes

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

Frequently Asked Questions

How Big is the Therapeutic Nuclear Medicine Market?

The market is set to be valued at US$ 1.32 billion in 2024.

What is the Therapeutic Nuclear Medicine Industry Supposed to be Worth in the Future?

The therapeutic nuclear medicine industry is anticipated to be valued at US$ 1.97 billion by 2034.

How Will the Therapeutic Nuclear Medicine Market Progress in the United Kingdom?

In the United Kingdom, demand is anticipated to develop at a CAGR of 3.5% by 2034.

Does Therapeutic Nuclear Medicine have a Future?

The therapeutic nuclear medicine industry is projected to register a CAGR of 4.10% from 2024 to 2034.

What are the Segments of the Therapeutic Nuclear Medicine Industry?

Therapeutic nuclear medicine industry has the following segments: treatment, indication, and distribution channel.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Product Life Cycle Analysis

3.5. Supply Chain Analysis

3.5.1. Supply Side Participants and their Roles

3.5.1.1. Manufacturer

3.5.1.2. Mid-Level Participants

3.5.1.3. Distributors

3.5.2. Value Added and Value Created at Node in the Supply Chain

3.5.3. List of Raw Material Suppliers

3.5.4. List of Existing and Potential Buyer’s

3.6. Investment Feasibility Matrix

3.7. Value Chain Analysis

3.7.1. Profit Margin Analysis

3.7.2. Distributors

3.8. PESTLE and Porter’s Analysis

3.9. Regulatory Landscape

3.9.1. By Key Regions

3.9.2. By Key Countries

3.10. Regional Parent Market Outlook

3.11. Production and Consumption Statistics

3.12. Import and Export Statistics

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023

4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Treatment, 2019 to 2023

5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Treatment, 2024 to 2034

5.3.1. Radium-223

5.3.2. Iodine-131

5.3.3. Leutitium-177

5.3.4. Yttrium-90

5.3.5. Samarium-153

5.3.6. Strontium-89

5.3.7. Rhenium-188+Rhenium-186

5.3.8. Erbium-169

5.3.9. Phosphorous-32

5.3.10. Others

5.4. Y-o-Y Growth Trend Analysis By Treatment, 2019 to 2023

5.5. Absolute $ Opportunity Analysis By Treatment, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Indication, 2019 to 2023

6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Indication, 2024 to 2034

6.3.1. Prostate Cancer

6.3.2. Painful Bone Metastases

6.3.3. Thyroid Cancer

6.3.4. Neuroblastoma

6.3.5. Synovitis

6.3.6. Non-Hodgkin’s Lymphoma

6.3.7. Hepatic Metastases

6.3.8. Brain Tumour

6.3.9. Others

6.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023

6.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023

7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034

7.3.1. Hospitals

7.3.2. Ambulatory Surgical Centres

7.3.3. Cancer Research Institutes

7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023

7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

8.1. Introduction

8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023

8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034

8.3.1. North America

8.3.2. Latin America

8.3.3. Western Europe

8.3.4. Eastern Europe

8.3.5. South Asia and Pacific

8.3.6. East Asia

8.3.7. Middle East and Africa

8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

9.2.1. By Country

9.2.1.1. USA

9.2.1.2. Canada

9.2.2. By Treatment

9.2.3. By Indication

9.2.4. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment

9.3.3. By Indication

9.3.4. By Distribution Channel

9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

10.2.1. By Country

10.2.1.1. Brazil

10.2.1.2. Mexico

10.2.1.3. Rest of Latin America

10.2.2. By Treatment

10.2.3. By Indication

10.2.4. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment

10.3.3. By Indication

10.3.4. By Distribution Channel

10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

11.2.1. By Country

11.2.1.1. Germany

11.2.1.2. UK

11.2.1.3. France

11.2.1.4. Spain

11.2.1.5. Italy

11.2.1.6. Rest of Western Europe

11.2.2. By Treatment

11.2.3. By Indication

11.2.4. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment

11.3.3. By Indication

11.3.4. By Distribution Channel

11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

12.2.1. By Country

12.2.1.1. Poland

12.2.1.2. Russia

12.2.1.3. Czech Republic

12.2.1.4. Romania

12.2.1.5. Rest of Eastern Europe

12.2.2. By Treatment

12.2.3. By Indication

12.2.4. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Treatment

12.3.3. By Indication

12.3.4. By Distribution Channel

12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

13.2.1. By Country

13.2.1.1. India

13.2.1.2. Bangladesh

13.2.1.3. Australia

13.2.1.4. New Zealand

13.2.1.5. Rest of South Asia and Pacific

13.2.2. By Treatment

13.2.3. By Indication

13.2.4. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Treatment

13.3.3. By Indication

13.3.4. By Distribution Channel

13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

14.2.1. By Country

14.2.1.1. China

14.2.1.2. Japan

14.2.1.3. South Korea

14.2.2. By Treatment

14.2.3. By Indication

14.2.4. By Distribution Channel

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Treatment

14.3.3. By Indication

14.3.4. By Distribution Channel

14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023

15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034

15.2.1. By Country

15.2.1.1. GCC Countries

15.2.1.2. South Africa

15.2.1.3. Israel

15.2.1.4. Rest of MEA

15.2.2. By Treatment

15.2.3. By Indication

15.2.4. By Distribution Channel

15.3. Market Attractiveness Analysis

15.3.1. By Country

15.3.2. By Treatment

15.3.3. By Indication

15.3.4. By Distribution Channel

15.4. Key Takeaways

16. Key Countries Market Analysis

16.1. USA

16.1.1. Pricing Analysis

16.1.2. Market Share Analysis, 2023

16.1.2.1. By Treatment

16.1.2.2. By Indication

16.1.2.3. By Distribution Channel

16.2. Canada

16.2.1. Pricing Analysis

16.2.2. Market Share Analysis, 2023

16.2.2.1. By Treatment

16.2.2.2. By Indication

16.2.2.3. By Distribution Channel

16.3. Brazil

16.3.1. Pricing Analysis

16.3.2. Market Share Analysis, 2023

16.3.2.1. By Treatment

16.3.2.2. By Indication

16.3.2.3. By Distribution Channel

16.4. Mexico

16.4.1. Pricing Analysis

16.4.2. Market Share Analysis, 2023

16.4.2.1. By Treatment

16.4.2.2. By Indication

16.4.2.3. By Distribution Channel

16.5. Germany

16.5.1. Pricing Analysis

16.5.2. Market Share Analysis, 2023

16.5.2.1. By Treatment

16.5.2.2. By Indication

16.5.2.3. By Distribution Channel

16.6. UK

16.6.1. Pricing Analysis

16.6.2. Market Share Analysis, 2023

16.6.2.1. By Treatment

16.6.2.2. By Indication

16.6.2.3. By Distribution Channel

16.7. France

16.7.1. Pricing Analysis

16.7.2. Market Share Analysis, 2023

16.7.2.1. By Treatment

16.7.2.2. By Indication

16.7.2.3. By Distribution Channel

16.8. Spain

16.8.1. Pricing Analysis

16.8.2. Market Share Analysis, 2023

16.8.2.1. By Treatment

16.8.2.2. By Indication

16.8.2.3. By Distribution Channel

16.9. Italy

16.9.1. Pricing Analysis

16.9.2. Market Share Analysis, 2023

16.9.2.1. By Treatment

16.9.2.2. By Indication

16.9.2.3. By Distribution Channel

16.10. Poland

16.10.1. Pricing Analysis

16.10.2. Market Share Analysis, 2023

16.10.2.1. By Treatment

16.10.2.2. By Indication

16.10.2.3. By Distribution Channel

16.11. Russia

16.11.1. Pricing Analysis

16.11.2. Market Share Analysis, 2023

16.11.2.1. By Treatment

16.11.2.2. By Indication

16.11.2.3. By Distribution Channel

16.12. Czech Republic

16.12.1. Pricing Analysis

16.12.2. Market Share Analysis, 2023

16.12.2.1. By Treatment

16.12.2.2. By Indication

16.12.2.3. By Distribution Channel

16.13. Romania

16.13.1. Pricing Analysis

16.13.2. Market Share Analysis, 2023

16.13.2.1. By Treatment

16.13.2.2. By Indication

16.13.2.3. By Distribution Channel

16.14. India

16.14.1. Pricing Analysis

16.14.2. Market Share Analysis, 2023

16.14.2.1. By Treatment

16.14.2.2. By Indication

16.14.2.3. By Distribution Channel

16.15. Bangladesh

16.15.1. Pricing Analysis

16.15.2. Market Share Analysis, 2023

16.15.2.1. By Treatment

16.15.2.2. By Indication

16.15.2.3. By Distribution Channel

16.16. Australia

16.16.1. Pricing Analysis

16.16.2. Market Share Analysis, 2023

16.16.2.1. By Treatment

16.16.2.2. By Indication

16.16.2.3. By Distribution Channel

16.17. New Zealand

16.17.1. Pricing Analysis

16.17.2. Market Share Analysis, 2023

16.17.2.1. By Treatment

16.17.2.2. By Indication

16.17.2.3. By Distribution Channel

16.18. China

16.18.1. Pricing Analysis

16.18.2. Market Share Analysis, 2023

16.18.2.1. By Treatment

16.18.2.2. By Indication

16.18.2.3. By Distribution Channel

16.19. Japan

16.19.1. Pricing Analysis

16.19.2. Market Share Analysis, 2023

16.19.2.1. By Treatment

16.19.2.2. By Indication

16.19.2.3. By Distribution Channel

16.20. South Korea

16.20.1. Pricing Analysis

16.20.2. Market Share Analysis, 2023

16.20.2.1. By Treatment

16.20.2.2. By Indication

16.20.2.3. By Distribution Channel

16.21. GCC Countries

16.21.1. Pricing Analysis

16.21.2. Market Share Analysis, 2023

16.21.2.1. By Treatment

16.21.2.2. By Indication

16.21.2.3. By Distribution Channel

16.22. South Africa

16.22.1. Pricing Analysis

16.22.2. Market Share Analysis, 2023

16.22.2.1. By Treatment

16.22.2.2. By Indication

16.22.2.3. By Distribution Channel

16.23. Israel

16.23.1. Pricing Analysis

16.23.2. Market Share Analysis, 2023

16.23.2.1. By Treatment

16.23.2.2. By Indication

16.23.2.3. By Distribution Channel

17. Market Structure Analysis

17.1. Competition Dashboard

17.2. Competition Benchmarking

17.3. Market Share Analysis of Top Players

17.3.1. By Regional

17.3.2. By Treatment

17.3.3. By Indication

17.3.4. By Distribution Channel

18. Competition Analysis

18.1. Competition Deep Dive

18.1.1. Bayer AG

18.1.1.1. Overview

18.1.1.2. Product Portfolio

18.1.1.3. Profitability by Market Segments

18.1.1.4. Sales Footprint

18.1.1.5. Strategy Overview

18.1.1.5.1. Marketing Strategy

18.1.1.5.2. Product Strategy

18.1.1.5.3. Channel Strategy

18.1.2. GE Healthcare

18.1.2.1. Overview

18.1.2.2. Product Portfolio

18.1.2.3. Profitability by Market Segments

18.1.2.4. Sales Footprint

18.1.2.5. Strategy Overview

18.1.2.5.1. Marketing Strategy

18.1.2.5.2. Product Strategy

18.1.2.5.3. Channel Strategy

18.1.3. Novartis AG

18.1.3.1. Overview

18.1.3.2. Product Portfolio

18.1.3.3. Profitability by Market Segments

18.1.3.4. Sales Footprint

18.1.3.5. Strategy Overview

18.1.3.5.1. Marketing Strategy

18.1.3.5.2. Product Strategy

18.1.3.5.3. Channel Strategy

18.1.4. Cardinal Health Inc.

18.1.4.1. Overview

18.1.4.2. Product Portfolio

18.1.4.3. Profitability by Market Segments

18.1.4.4. Sales Footprint

18.1.4.5. Strategy Overview

18.1.4.5.1. Marketing Strategy

18.1.4.5.2. Product Strategy

18.1.4.5.3. Channel Strategy

18.1.5. Mallinckrodt plc.

18.1.5.1. Overview

18.1.5.2. Product Portfolio

18.1.5.3. Profitability by Market Segments

18.1.5.4. Sales Footprint

18.1.5.5. Strategy Overview

18.1.5.5.1. Marketing Strategy

18.1.5.5.2. Product Strategy

18.1.5.5.3. Channel Strategy

18.1.6. Lantheus Medical Imaging Inc.

18.1.6.1. Overview

18.1.6.2. Product Portfolio

18.1.6.3. Profitability by Market Segments

18.1.6.4. Sales Footprint

18.1.6.5. Strategy Overview

18.1.6.5.1. Marketing Strategy

18.1.6.5.2. Product Strategy

18.1.6.5.3. Channel Strategy

18.1.7. Bracco Imaging S.p.A

18.1.7.1. Overview

18.1.7.2. Product Portfolio

18.1.7.3. Profitability by Market Segments

18.1.7.4. Sales Footprint

18.1.7.5. Strategy Overview

18.1.7.5.1. Marketing Strategy

18.1.7.5.2. Product Strategy

18.1.7.5.3. Channel Strategy

18.1.8. Eckert & Ziegler

18.1.8.1. Overview

18.1.8.2. Product Portfolio

18.1.8.3. Profitability by Market Segments

18.1.8.4. Sales Footprint

18.1.8.5. Strategy Overview

18.1.8.5.1. Marketing Strategy

18.1.8.5.2. Product Strategy

18.1.8.5.3. Channel Strategy

18.1.9. Curium Pharma

18.1.9.1. Overview

18.1.9.2. Product Portfolio

18.1.9.3. Profitability by Market Segments

18.1.9.4. Sales Footprint

18.1.9.5. Strategy Overview

18.1.9.5.1. Marketing Strategy

18.1.9.5.2. Product Strategy

18.1.9.5.3. Channel Strategy

18.1.10. International Isotopes Idaho, Inc.

18.1.10.1. Overview

18.1.10.2. Product Portfolio

18.1.10.3. Profitability by Market Segments

18.1.10.4. Sales Footprint

18.1.10.5. Strategy Overview

18.1.10.5.1. Marketing Strategy

18.1.10.5.2. Product Strategy

18.1.10.5.3. Channel Strategy

18.1.11. Medi-Radiopharma Co., Ltd.

18.1.11.1. Overview

18.1.11.2. Product Portfolio

18.1.11.3. Profitability by Market Segments

18.1.11.4. Sales Footprint

18.1.11.5. Strategy Overview

18.1.11.5.1. Marketing Strategy

18.1.11.5.2. Product Strategy

18.1.11.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Therapeutic Nuclear Medicine Market

Therapeutic Nuclear Medicine Market Forecast by Prostate Cancer and Thyroid Cancer for 2024 to 2034